Immunotherapy IRC @fredhutch

Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma.  @Fredhutch Matthias Stephan Lab discovery: new mRNA-based foam coats the esophagus, delivering apoptosis-inducing therapy directly to tumors. In vitro, it showed 110× higher tumor regression than suspension and boosted radiotherapy effects—offering hope for home-based, less disruptive treatment. Matthias Stephan to present findings at Digestive Disease Week: ddw.org/?doing_wp_cron…

CSF-1R inhibition and lenalidomide synergize to promote myeloma control after autologous stem cell transplantation ashpublications.org/blood/article/…

@fredhutch investigators found that young ALL patients in third or later remission were more likely than those in second remission to experience transplant-associated mortality after transplant, highlighting the critical need for new strategies to reduce side-effects in patients in third remission or beyond and to strongly consider transplantation in second remission." bit.ly/4rccFA0 Transplantation of donor-derived blood-forming stem cells is commonly used to treat patients with recurrent acute lymphoblastic leukemia (ALL), reducing relapse risk but sometimes causing significant toxicities.

@fredhutch investigators found that young ALL patients in third or later remission were more likely than those in second remission to experience transplant-associated mortality after transplant, highlighting the critical need for new strategies to reduce side-effects in patients in third remission or beyond and to strongly consider transplantation in second remission. bit.ly/4rccFA0 Transplantation of donor-derived blood-forming stem cells is commonly used to treat patients with recurrent acute lymphoblastic leukemia (ALL), reducing relapse risk but sometimes causing significant toxicities.

"Huge thanks to an amazing team, mentors, and collaborators at @fredhutch @FH_IRC and globally 📄 Nature: “The ubiquitin ligase KLHL6 drives resistance to CD8⁺ T cell dysfunction” 🔗 (nature.com/articles/s4158…)

@HutchInnovation @fredhutch Evaluating the practical aspects and performance of commercial single-cell RNA sequencing technologies academic.oup.com/nargab/article…

@hutchinnovation, @fredhutch Evaluating the practical aspects and performance of commercial single-cell RNA sequencing technologies academic.oup.com/nargab/article…

Immune T cells can be genetically engineered to express “T cell receptors (TCRs)” that target specific molecules on cancer cells, but these cell-based therapies have shown limited clinical efficacy for patients with solid tumors, hindered by insufficient trafficking, persistence and anti-tumor function of the engineered T cells. @fredhutch investigators have now designed a chimeric TCR-containing engineering vehicle that improves tumor control in multiple laboratory models, supporting its broad utility. Read more: bit.ly/4qgglRg

Eomesodermin+ CD4+ T cells are critical for curative immunotherapy outcomes: Immunity cell.com/immunity/fullt…

Cell therapy legend Prof. Rainer Storb, recipient of the Wallace H. Coulter Award, prefacing the #ASH25 Plenary Session in front of a packed room. 🙌 @fredhutch #fanboy

Fred Hutch at #ASH25: Dr. Danielle Kirkey & team identified CLEC2A as a cancer-specific antigen in AML — silent in normal cells, enriched in high-risk KMT2A-r AML. CLEC2A CAR T cells showed strong preclinical efficacy & head to clinical trials in 2026. #AML #CARTherapy

Cytomegalovirus (CMV)-specific T-cell function after hematopoietic cell transplantation (HCT). Immune T cells are critical for antiviral immunity, including after highly immunosuppressive HCT to reduce serious complications. @fredhutch scientists determined that post-transplant cyclophosphamide spared anti-CMV T-cell function at 3 months after HCT. The study found cyclosporine permitted a more robust CMV-specific T cell reconstitution than tacrolimus, while high-dose steroids & prolonged high-dose mycophenolate mofetil suppressed anti-viral T cell polyfunctionality unless rapidly tapered. These insights can be used to optimize CMV management, HCT and other cellular therapies. Read more: bit.ly/4oBlEZA

Fred Hutch #BMT and #GVHD expert Dr. Geoffrey Hill (@Geoff_Hill_Lab) spoke to Fred Hutch News about the lifesaving strides that have been made in GVHD treatment, and where the research is focused next. Read more: bit.ly/48FyccO

Gene-edited stem cell engraftment in primates. Genetically engineered hematopoietic stem cell (HSC) therapies can provide lifelong benefit for patients with numerous diseases, including HIV, but the chemotherapy used to “condition” for the therapeutic stem cells can be very toxic. @fredhutch investigators showed that conditioning with antibody-drug conjugates was also able to support engraftment of gene-edited and HIV-resistant stem cells in rhesus monkeys. However further refinements and higher levels are still needed. Read more: bit.ly/44NqThL

@fredhutch Congrats from the IIRC! Exciting news, indeed!

The world is a few steps closer to a cure for #HIV, a hopeful sign illuminated by two studies published Monday featuring work from Fred Hutch's Lillian Cohn, Daniel Reeves and others. #WorldAIDSDay bit.ly/44JxZ6X

Among 10k+ blood cancer patients who received stem cell transplants from unrelated donors, posttransplant cyclophosphamide was associated with lower age-related risks than conventional calcineurin inhibitor treatments, potentially expanding the donor pool. bit.ly/48pXkoI, @fredhutch